Chemomab Therapeutics (CMMB) Change in Account Payables (2018 - 2023)
Chemomab Therapeutics (CMMB) posted Change in Account Payables of -$215000.0 for Q4 2023, up 86.7% on a QoQ basis from -$1.6 million in Q3 2023, and down 148.75% year-over-year from $441000.0 in Q4 2022.
Chemomab Therapeutics (CMMB) Change in Account Payables (2018 - 2023) Analysis & Trends
Chemomab Therapeutics' Change in Account Payables history runs 6 years deep, the most recent figure standing at -$215000.0 for Q4 2023.
- Quarterly Change in Account Payables fell 148.75% year-over-year to -$215000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was -$1.2 million (down 432.95% YoY) and the FY2025 annual result came in at -$177000.0, down 251.28% from the prior year.
- Change in Account Payables was -$215000.0 for Q4 2023 at Chemomab Therapeutics, up from -$1.6 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $854000.0 in Q4 2021 and bottomed at -$1.6 million in Q3 2023.
- A 5-year average of $74950.0 and a median of $98000.0 in 2020 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2021 — Change in Account Payables soared 1193.94% — and 2022, when it plunged 2166.67%.
- Chemomab Therapeutics' Change in Account Payables stood at $163000.0 in 2019, then plunged by 59.51% to $66000.0 in 2020, then surged by 1193.94% to $854000.0 in 2021, then tumbled by 48.36% to $441000.0 in 2022, then slumped by 148.75% to -$215000.0 in 2023.
- Business Quant data shows CMMB's Change in Account Payables at -$215000.0 in Q4 2023, -$1.6 million in Q3 2023, and $130000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | Chemomab Therapeutics | 124.14 Mn | 113.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -215,000.00 |
| Dec 31, 2023 | -215,000.00 |
| Sep 30, 2023 | -1.62 Mn |
| Sep 30, 2023 | -1.62 Mn |
| Jun 30, 2023 | 130,000.00 |
| Jun 30, 2023 | 130,000.00 |
| Mar 31, 2023 | 529,000.00 |
| Mar 31, 2023 | 529,000.00 |
| Dec 31, 2022 | 441,000.00 |
| Dec 31, 2022 | 441,000.00 |
| Sep 30, 2022 | -186,000.00 |
| Sep 30, 2022 | -186,000.00 |
| Jun 30, 2022 | -54,000.00 |
| Jun 30, 2022 | -54,000.00 |
| Mar 31, 2022 | 151,000.00 |
| Mar 31, 2022 | 151,000.00 |
| Dec 31, 2021 | 854,000.00 |
| Dec 31, 2021 | 854,000.00 |
| Sep 30, 2021 | 9,000.00 |
| Sep 30, 2021 | 9,000.00 |